nach oben

Der Nervenarzt

Erschienen in:

01.04.2013 | Leitthema

Neuromyelitis optica

verfasst von: Prof. Dr. B. Wildemann, S. Jarius, F. Paul

Erschienen in: Der Nervenarzt | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Entdeckung eines Serumautoantikörpers gegen das astrozytäre Wasserkanalprotein Aquaporin-4 (AQP4) als Biomarker der Neuromyelitis optica (NMO, Devic-Syndrom) hat das Verständnis über diese seltene immunvermittelte klinische Entität revolutioniert und ein rational begründetes therapeutisches Vorgehen ermöglicht. In dieser Übersicht stellen wir die klinischen Besonderheiten der NMO sowie neue Erkenntnisse zur pathophysiologischen Bedeutung der gegen Aquaporin-4 gerichteten humoralen und zellulären Immunantwort dar.

Akman-Demir G, Tuzun E, Waters P et al (2011) Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol 258:464–470PubMedCrossRef

Arellano B, Hussain R, Zacharias T et al (2012) Human Aquaporin 4281-300 is the immunodominant linear determinant in the context of HLA-DRB1*03:01: relevance for diagnosing and monitoring patients with neuromyelitis optica. Arch Neurol 69:1125–1131PubMedCrossRef

Bourre B, Marignier R, Zephir H et al (2012) Neuromyelitis optica and pregnancy. Neurology 78:875–879PubMedCrossRef

Chihara N, Aranami T, Sato W et al (2011) Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A 108:3701–3706PubMedCrossRef

Collongues N, Cabre P, Marignier R et al (2011) A benign form of neuromyelitis optica: does it exist? Arch Neurol 68:918–924PubMedCrossRef

Huppke P, Bluthner M, Bauer O et al (2010) Neuromyelitis optica and NMO-IgG in European pediatric patients. Neurology 75:1740–1744PubMedCrossRef

Jarius S, Wildemann B (2007) Neuromyelitis optica. Nervenarzt 78:1365–1377PubMedCrossRef

Jarius S, Aboul-Enein F, Waters P et al (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131:3072–3080PubMedCrossRef

Jarius S, Franciotta D, Bergamaschi R et al (2008) Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 79:1134–1136PubMedCrossRef

10.

Jarius S, Paul F, Franciotta D et al (2008) Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4:202–214PubMed

11.

Jarius S, Frederikson J, Waters P et al (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298:158–162PubMedCrossRef

12.

Jarius S, Probst C, Borowski K et al (2010) Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 291:52–56PubMedCrossRef

13.

Jarius S, Wildemann B (2010) AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6:383–392PubMedCrossRef

14.

Jarius S, Jacobi C, Seze J de et al (2011) Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 17:1067–1073PubMedCrossRef

15.

Jarius S, Paul F, Franciotta D et al (2011) Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 306:82–90PubMedCrossRef

16.

Jarius S, Wildemann B (2011) An early case of neuromyelitis optica: on a forgotten report by Jacob Lockhart Clarke, FRS. Mult Scler 17:1384–1386PubMedCrossRef

17.

Jarius S, Franciotta D, Paul F et al (2012) Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci 320:32–37PubMedCrossRef

18.

Jarius S, Paul F, Franciotta D et al (2012) Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler 18:1135–1143PubMedCrossRef

19.

Jarius S, Paul F, Ruprecht K et al (2012) Low vitamin B12 levels and gastric parietal cell antibodies in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders. J Neurol doi:10.1007/s00415-012-6677-1

20.

Jarius S, Ruprecht K, Wildemann B et al (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14PubMedCrossRef

21.

Jarius S, Wandinger KP, Borowski K et al (2012) Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg 114:331–335PubMedCrossRef

22.

Jarius S, Wildemann B (2012) ‚Noteomielite‘ accompanied by acute amaurosis (1844). An early case of neuromyelitis optica. J Neurol Sci 313:182–184PubMedCrossRef

23.

Jarius S, Wildemann B (2012) The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation. J Neurol 259:1354–1357PubMedCrossRef

24.

Jarius S, Wildemann B (2013) On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. J Neurol 260:100–104PubMedCrossRef

25.

Kalluri SR, Rothhammer V, Staszewski O et al (2011) Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. PLoS One 6:e16083PubMedCrossRef

26.

Khatri BO, Kramer J, Dukic M et al (2012) Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. J Clin Apher 27:183–192PubMedCrossRef

27.

Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135:1834–1849PubMedCrossRef

28.

Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79:1273–1277PubMedCrossRef

29.

Kleiter I, Hellwig K, Berthele A et al (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69:239–245PubMedCrossRef

30.

Leite MI, Coutinho E, Lana-Peixoto M et al (2012) Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 78:1601–1607PubMedCrossRef

31.

Lennon VA, Wingerchuk DM, Kryzer TJ et al (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112PubMedCrossRef

32.

Lennon VA, Kryzer TJ, Pittock SJ et al (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477PubMedCrossRef

33.

Li Y, Wang H, Long Y et al (2011) Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis. J Neuroimmunol 234:155–160PubMedCrossRef

34.

Lucchinetti CF, Mandler RN, McGavern D et al (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 125:1450–1461PubMedCrossRef

35.

Mader S, Gredler V, Schanda K et al (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8:184PubMedCrossRef

36.

Matiello M, Lennon VA, Jacob A et al (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70:2197–2200PubMedCrossRef

37.

Matiello M, Sun D, Schaefer-Klein J et al (2012) Tissue Susceptibility to Neuromyelitis Optica Is Associated with Aquaporin-4 Expression and Supramolecular Aggregation. Neurology 78:S60.001CrossRef

38.

Matsuya N, Komori M, Nomura K et al (2011) Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. Int Immunol 23:565–573PubMedCrossRef

39.

McKeon A, Lennon VA, Lotze T et al (2008) CNS aquaporin-4 autoimmunity in children. Neurology 71:93–100PubMedCrossRef

40.

Mealy MA, Wingerchuk DM, Greenberg BM et al (2012) Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol 69:1176–1180PubMedCrossRef

41.

Nelson PA, Khodadoust M, Prodhomme T et al (2010) Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. PLoS One 5:e15050PubMedCrossRef

42.

Papadopoulos MC, Verkman AS (2012) Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11:535–544PubMedCrossRef

43.

Paul F, Jarius S, Aktas O et al (2007) Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 4:e133PubMedCrossRef

44.

Paul F, Jarius S, Glumm R et al (2008) Recent findings in pathogenesis, diagnostics and therapy of neuromyelitis optica. Dtsch Med Wochenschr 133:1125–1129PubMedCrossRef

45.

Pellkofer HL, Krumbholz M, Berthele A et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76:1310–1315PubMedCrossRef

46.

Pfueller CF, Paul F (2011) Imaging the visual pathway in neuromyelitis optica. Mult Scler Int 2011:Article ID 869814

47.

Pittock SJ, Lennon VA, Krecke K et al (2006) Brain abnormalities in neuromyelitis optica. Arch Neurol 63:390–396PubMedCrossRef

48.

Pohl M, Fischer MT, Mader S et al (2011) Pathogenic T cell responses against aquaporin 4. Acta Neuropathol 122:21–34PubMedCrossRef

49.

Ratelade J, Zhang H, Saadoun S et al (2012) Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss. Acta Neuropathol 123:861–872PubMedCrossRef

50.

Saadoun S, Waters P, MacDonald C et al (2012) Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol 71:323–333PubMedCrossRef

51.

Takahashi T, Fujihara K, Nakashima I et al (2007) Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130:1235–1243PubMedCrossRef

52.

Tradtrantip L, Zhang H, Saadoun S et al (2012) Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 71:314–322PubMedCrossRef

53.

Trebst C, Raab P, Voss EV et al (2011) Longitudinal extensive transverse myelitis–it’s not all neuromyelitis optica. Nat Rev Neurol 7:688–698PubMedCrossRef

54.

Tuzun E, Kurtuncu M, Turkoglu R et al (2011) Enhanced complement consumption in neuromyelitis optica and Behcet’s disease patients. J Neuroimmunol 233:211–215PubMedCrossRef

55.

Vaknin-Dembinsky A, Brill L, Kassis I et al (2012) T-cell reactivity against AQP4 in neuromyelitis optica. Neurology 79:945–946PubMedCrossRef

56.

Varrin-Doyer M, Spencer CM, Schulze-Topphoff U et al (2012) Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 72:53–64PubMedCrossRef

57.

Wang HH, Dai YQ, Qiu W et al (2011) Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci 18(10):1313–1317PubMedCrossRef

58.

Warabi Y, Yagi K, Hayashi H et al (2006) Characterization of the T cell receptor repertoire in the Japanese neuromyelitis optica: T cell activity is up-regulated compared to multiple sclerosis. J Neurol Sci 249:145–152PubMedCrossRef

59.

Weinshenker BG, Wingerchuk DM, Vukusic S et al (2006) Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 59:566–569PubMedCrossRef

60.

Wildemann B, Jarius S, Paul F (2012) Neuromyelitis optica. Akt Neurol 39:33–41CrossRef

61.

Wingerchuk DM, Lennon VA, Pittock SJ et al (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489PubMedCrossRef

62.

Jarius S, Wildemann B (2012). An early British case of neuromyelitis optica (1850). BMJ 345:e6430PubMedCrossRef

63.

Jarius S, Wildemann B (2013). The history of neuromyelitis optica. J Neuroinflammation (in print)

Titel: Neuromyelitis optica
verfasst von: Prof. Dr. B. Wildemann
S. Jarius
F. Paul
Publikationsdatum: 01.04.2013
Verlag: Springer-Verlag
Erschienen in: Der Nervenarzt / Ausgabe 4/2013
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-012-3602-x

Neu in den Fachgebieten Neurologie und Psychiatrie

23.04.2024 | Demenz | Nachrichten

Springer Medizin

Neuromyelitis optica

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Das Stiff-Man-Syndrom und seine Varianten

Immunvermittelte Epilepsien und Enzephalopathien

Spinale Prodromalphase einer Anti-NMDA-Rezeptor-Enzephalitis

Therapeutische Apherese bei autoimmuner Enzephalitis

Immunvermittelte Enzephalomyelitiden

Autoantikörperdiagnostik in der Neurologie mittels nativer und rekombinanter Antigensubstrate

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein